The FDA has published a comprehensive guidance recommendation to assist biosimilar applicants with manufacturing changes. Through the question-and-answer format, the FDA provides insights and recommendations to promote the development of these important therapeutic alternatives, while also seeking to collaborate with industry to effectively shape future biosimilar guidance.
